BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 33049225)

  • 41. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases.
    Tomizawa D; Yoshida M; Kondo T; Miyamura T; Taga T; Adachi S; Koh K; Noguchi M; Kakuda H; Watanabe K; Cho Y; Fukuda T; Kato M; Shiba N; Goto H; Okada K; Inoue M; Hashii Y; Atsuta Y; Ishida H
    Bone Marrow Transplant; 2019 Mar; 54(3):393-401. PubMed ID: 29959436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.
    Oran B; Popat U; Rondon G; Ravandi F; Garcia-Manero G; Abruzzo L; Andersson BS; Bashir Q; Chen J; Kebriaei P; Khouri IF; Koca E; Qazilbash MH; Champlin R; de Lima M
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):214-20. PubMed ID: 22982533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
    Moukalled N; Labopin M; Versluis J; Socié G; Blaise D; Salmenniemi U; Rambaldi A; Gedde-Dahl T; Tholouli E; Kröger N; Bourhis JH; Von Dem Borne P; Daguindau E; Forcade E; Nagler A; Esteve J; Ciceri F; Bazarbachi A; Mohty M
    Am J Hematol; 2024 Mar; 99(3):360-369. PubMed ID: 38165072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
    Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
    Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
    Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
    Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Qian T; Quan L; Cui W; Pan Y; Ye X; Shi J; Fu L
    Cancer Biol Ther; 2019; 20(10):1314-1318. PubMed ID: 31306053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
    Lou D; Liu L; Yan XQ; Gu FN; Zhang YP; Qin WW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
    Zhou W; Chen G; Gong D; Gao Y; Yu L
    Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
    Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
    Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
    Poiani M; Labopin M; Battipaglia G; Beelen DW; Tischer J; Finke J; Brecht A; Forcade E; Ganser A; Passweg JR; Labussiere-Wallet H; Yakoub-Agha I; Schäfer-Eckart K; Kroeger N; Guffroy B; Ruggeri A; Esteve J; Nagler A; Mohty M
    Am J Hematol; 2021 Jan; 96(1):40-50. PubMed ID: 32944990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
    Konuma T; Kondo T; Yamashita T; Uchida N; Fukuda T; Ozawa Y; Ohashi K; Ogawa H; Kato C; Takahashi S; Kanamori H; Eto T; Nakaseko C; Kohno A; Ichinohe T; Atsuta Y; Takami A; Yano S;
    Ann Hematol; 2017 Mar; 96(3):469-478. PubMed ID: 28058493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.